相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略:5 种常见类型+关键误区Cytoscape 教程来了!快速实现顶刊同款通路网络图五大应用案例:Mustang Q 膜层析应用全解析1 个小工具,一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
1373423-53-0
- 规格:
10 mM * 1 mL/5 mg/10 mg/25 mg/50 mg/100 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥825.0 |
|---|---|---|---|
| 规格: | 5 mg | 产品价格: | ¥750.0 |
| 规格: | 10 mg | 产品价格: | ¥1195.0 |
| 规格: | 25 mg | 产品价格: | ¥2300.0 |
| 规格: | 50 mg | 产品价格: | ¥3600.0 |
| 规格: | 100 mg | 产品价格: | ¥4713.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
GSK-J4
CAS No. : 1373423-53-0
MCE 国际站:GSK-J4
产品活性:GSK-J4 是一种有效的 H3K27me3/me2 去甲基化酶 JMJD3/KDM6B 和 UTX/KDM6A 双抑制剂,IC50 分别为 8.6 μM 和 6.6 μM。GSK-J4 抑制 LPS 诱导的人原代巨噬细胞产生 TNF-α,IC50 值为 9 μM。GSK-J4 是 GSK-J1 的细胞通透性前体。GSK-J4 诱导内质网应激相关的细胞凋亡 (apoptosis)。
研究领域:Epigenetics | Apoptosis
作用靶点:Histone Demethylase | Apoptosis
In Vitro: GSK-J4 has cellular activity in Flag-JMJD3-transfected HeLa cells, in which GSK-J4 prevents the JMJD3-induced loss of nuclear H3K27me3 immunostaining. Administration of GSK-J4 increases total nuclear H3K27me3 levels in untransfected cells. GSK-J4 significantly reduces the expression of 16 of 34 LPS-driven cytokines, including tumour-necrosis factor-α (TNF-α).
GSK-J4 (5 μM; 48 hours) causes a more than 3-fold increase in mouse podocyte H3K27me3 content. H3K27me3 levels in cultured podocytes, GSK-J4 reduces Jagged-1 mRNA and Jagged-1 protein levels. Correspondingly, when exposed podocytes to the inducer of dedifferentiation TGF-β1, pretreatment with GSK-J4 preventes both the increase in intracellular N1-ICD levels and the increase in α-SMA and the decrease in podocin mRNA levels.
GSK-J4 (10, 25 nM) acts upon DCs promoting the differentiation of Treg cells, improving Treg stability and suppressive capacities, without affecting the differentiation of Th1 and Th17 cells.
GSK-J4 inhibits JMJD3 expression that is induced by TGF-β1.
GSK-J4 inhibits H3K4 demethylation at Xist, Nodal, and HoxC13 in female embryonic stem cells.
In Vivo: GSK-J4 Hydrochloride (10 mg/kg; i.p.; thrice-weekly for 10 weeks) attenuates the development of kidney disease in diabetic mice.
GSK-J4 (0.5 mg/kg, i.p.) significantly reduces the severity and delays the onset of the disease of the mouse model of experimental autoimmune encephalomyelitis.
相关产品:Bioactive Compound Library Plus | Apoptosis Compound Library | Epigenetics Compound Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Anti-diabetic Compound Library | Endoplasmic Reticulum Stress Compound Library | Chemical Probe Library | Anti-Cancer Metabolism Compound Library | Human Metabolite Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Cell Death Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Monomethyl auristatin E
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验. (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. BiochimBiophys Acta. 1114 , 147–162. 2. Frame S, Cohen P. (2001) GSK3 takes centrestage more than 20 years after its discovery. Biochem J. 359 , 1–16. 3. Doble BW
Adv Sci∣周祥团队合作揭示通过工程化外泌体诱导肿瘤细胞核仁应激的分子机制与策略
p53 蛋白是最重要的肿瘤抑制因子,被称作「基因组卫士」, 在预防和控制肿瘤的形成及发展中发挥着至关重要的作用。它能够被多种细胞应激信号激活,例如,在发生核仁应激时,游离的核糖体蛋白(如 RPL5 和 RPL11)从核仁释放到核质中,与 MDM2 结合,抑制 MDM2 对 p53 的泛素化降解,进而促进 p53 蛋白的稳定和活化。因此,将核仁蛋白作为靶点,通过触发核仁应激–p53 这一途径来抑制肿瘤的生长,有望成为一种有效的肿瘤靶向治疗策略。 日前,复旦大学生物医学研究院/附属肿瘤医院周祥
砷剂疗法的前世今生:「吃最毒的药,治最难的病」,「砒霜」抗癌再登 Cell 子刊
在其他癌症的疗效飘忽不定,并不像它在 APL 中那样能够化腐朽为神奇。 如何让 ATO 更有效的帮助其他癌症的患者,成为了砷剂研究者们下一个需要解决的问题。而精准医疗概念的兴起,为砷剂研究者们指明了新的方向。 图片来源:Cancer Cell 2020 年 12 月 24 号,来自上海交通大学瑞金医学的卢敏团队在 Cell 子刊 Cancer Cell 上发表了题为 Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic
技术资料暂无技术资料 索取技术资料


















